 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...63646566676869707172737475» |
- ||| Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Enrollment open: Ranibizumab Treatment for Retinal Vein Occlusion (clinicaltrials.gov) - Oct 19, 2013
P=N/A, N=100, Recruiting, Sponsor: Kyoto University, Graduate School of Medicine
Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia (clinicaltrials.gov) - Oct 18, 2013
P1, N=60, Completed, Sponsor: Second University of Naples
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Enrollment closed: Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (clinicaltrials.gov) - Oct 16, 2013
P4, N=110, Active, not recruiting, Sponsor: University of Cologne
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: SALT: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (clinicaltrials.gov) - Oct 7, 2013
P4, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 23, 2013
P3, N=670, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (clinicaltrials.gov) - Sep 22, 2013
P3, N=644, Ongoing, Sponsor: Novartis Farmac
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Sep 17, 2013
P2, N=125, Recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
- |||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment open: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Sep 17, 2013
P3, N=475, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Fovista (pegpleranib) / Roche, Astellas
New P3 trial, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Sep 16, 2013
P3, N=622, Recruiting, Sponsor: Ophthotech Corporation
- || Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial, Monotherapy: PROTEUS: Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (clinicaltrials.gov) - Sep 11, 2013
P2/3, N=94, Not yet recruiting, Sponsor: Association for Innovation and Biomedical Research on Light and Image
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RELIGHT: Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment (clinicaltrials.gov) - Sep 10, 2013
P4, N=111, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (clinicaltrials.gov) - Sep 9, 2013
P1/2, N=150, Recruiting, Sponsor: Palmetto Retina Center, LLC
Recruiting --> Completed N=90 --> 150
- |||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration (clinicaltrials.gov) - Sep 9, 2013
P1/2, N=100, Recruiting, Sponsor: Arshad Khanani
N=90 --> 150 Not yet recruiting --> Recruiting
- || Fovista (pegpleranib) / Roche, Astellas
New P3 trial, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Sep 8, 2013
P3, N=622, Recruiting, Sponsor: Ophthotech Corporation
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, HEOR: Protocol T: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Sep 3, 2013
P3, N=660, Active, not recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (clinicaltrials.gov) - Sep 2, 2013
P1/2, N=150, Recruiting, Sponsor: Palmetto Retina Center, LLC
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: OPTIMAL: Ranibizumab "Treat and Extend" in Diabetic Macular Edma (clinicaltrials.gov) - Aug 26, 2013
P4, N=7, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=30 --> 7
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: OPTIMAL: Ranibizumab "Treat and Extend" in Diabetic Macular Edma (clinicaltrials.gov) - Aug 26, 2013
P4, N=7, Completed, Sponsor: Novartis Pharmaceuticals
N=30 --> 7 Recruiting --> Completed
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye (clinicaltrials.gov) - Aug 20, 2013
P3, N=10, Completed, Sponsor: Queen's University
Recruiting --> Completed Recruiting --> Completed
- ||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration (clinicaltrials.gov) - Aug 19, 2013
P1/2, N=100, Recruiting, Sponsor: Arshad Khanani
- |||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment open, Combination therapy, Monotherapy: EVEREST II: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (clinicaltrials.gov) - Aug 19, 2013
P4, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions (clinicaltrials.gov) - Aug 19, 2013
P1/2, N=40, Completed, Sponsor: Peter A Campochiaro, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma (clinicaltrials.gov) - Aug 12, 2013
P4, N=15, Completed, Sponsor: Siriraj Hospital
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
New P3 trial: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Aug 12, 2013
P3, N=475, Recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma (clinicaltrials.gov) - Aug 12, 2013
P4, N=15, Completed, Sponsor: Siriraj Hospital
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Aug 11, 2013
P2, N=131, Active, not recruiting, Sponsor: Lawrence S. Morse, MD
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema (clinicaltrials.gov) - Aug 4, 2013
P=N/A, N=300, Recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment (clinicaltrials.gov) - Jul 31, 2013
P4, N=6, Completed, Sponsor: Vitreous -Retina- Macula Consultants of New York
Not yet recruiting --> Recruiting N=25 --> 6
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment (clinicaltrials.gov) - Jul 31, 2013
P4, N=6, Completed, Sponsor: Vitreous -Retina- Macula Consultants of New York
N=25 --> 6 Recruiting --> Completed
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) (clinicaltrials.gov) - Jul 31, 2013
P3, N=382, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema (clinicaltrials.gov) - Jul 31, 2013
P1/2, N=50, Completed, Sponsor: Philip J. ferrone, M.D.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study (clinicaltrials.gov) - Jul 30, 2013
P2, N=30, Recruiting, Sponsor: University Hospital, Bonn
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) (clinicaltrials.gov) - Jul 30, 2013
P3, N=377, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination, Surgery: Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery (clinicaltrials.gov) - Jul 24, 2013
P=N/A, N=11, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Completed --> Terminated; low recruitment
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, New P3 trial: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jul 24, 2013
P3, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: COMRADE-B: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Jul 24, 2013
P3, N=244, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; low recruitment Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion Wiederbehandlung mit Ranibizumab bei Patienten mit Makula (EUDRACT) - Jul 22, 2013
P2, N=24, Ongoing, Sponsor: University of Leipzig Ritterstr. 26, 04109 Leipzig
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Efficacy Study of Lucentis in the Treatment of Retinoblastoma (clinicaltrials.gov) - Jul 11, 2013
P2, N=20, Recruiting, Sponsor: Sun Yat-sen University
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: ORION: Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (clinicaltrials.gov) - Jul 4, 2013
P4, N=45, Recruiting, Sponsor: Valley Retina Institute
Recruiting --> Completed Not yet recruiting --> Recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Ranibizumab and Vitrectomy in the Therapy of Diabetic Macular Edema (The RAVIT-DME-Trial) (EUDRACT) - Jun 23, 2013
P3, N=110, Ongoing, Sponsor: `Augenklinik Universitaetsallee
- Lucentis (ranibizumab) / Roche, Novartis, iCo-007 / Ionis
Enrollment closed, Combination therapy, Monotherapy: iDEALt: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) (clinicaltrials.gov) - Jun 23, 2013
P2, N=208, Active, not recruiting, Sponsor: Quan Dong Nguyen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: PEARL2t: Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) (clinicaltrials.gov) - Jun 20, 2013
P1/2, N=24, Active, not recruiting, Sponsor: Hawaii Pacific Health
- |||| Beovu (brolucizumab-dbll) / Novartis
Enrollment open: ESBA1008 Microvolume Study (clinicaltrials.gov) - Jun 20, 2013
P2, N=52, Recruiting, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=115, Active, not recruiting, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: POLARIS: Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy (clinicaltrials.gov) - Jun 9, 2013
P=N/A, N=807, Recruiting, Sponsor: Bayer
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: RETAIN: Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion (clinicaltrials.gov) - Jun 7, 2013
P3, N=66, Completed, Sponsor: Peter A Campochiaro, MD
Not yet recruiting --> Recruiting N=25 --> 66
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: RELATE: Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions (clinicaltrials.gov) - Jun 7, 2013
P1/2, N=80, Active, not recruiting, Sponsor: Peter A Campochiaro, MD
N=25 --> 66 Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RETAIN: Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion (clinicaltrials.gov) - Jun 7, 2013
P3, N=66, Completed, Sponsor: Peter A Campochiaro, MD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot (clinicaltrials.gov) - Jun 7, 2013
P2, N=6, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RAP: Ranibizumab and Reduced Fluence PDT for AMD (clinicaltrials.gov) - Jun 4, 2013
P2, N=60, Completed, Sponsor: Texas Retina Associates
Active, not recruiting --> Completed Active, not recruiting --> Completed